Gilead Sciences

Cowen analysts recently released a research report that focused on biotech stocks with promising Phase 3 data leading into the U.S. Food and Drug Administration (FDA) approval process. ACADIA Pharmaceuticals (NASDAQ: ACAD), Alexion Pharmaceuticals (NASDAQ: ALXN), InterMune (NASDAQ: ITMN) and...

While Amgen (NASDAQ: AMGN) saw a sizable dip in short interest between the April 30 and May 15 settlement dates, short sellers piled on Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC). Among other leading biotechs and emerging pharmaceuticals, gains in the number of their shares sold...

When it comes to the biotech industry, it’s hard to stay in the loop without following Gilead Sciences (NASDAQ: GILD). That being the case, investors might be interested in the company’s Phase 2 study results of HARMONY that were released this weekend. HARMONY is a randomized, double-blind,...

Biotech stocks have proved to be volatile this year, and short sellers piled on Incyte (NASDAQ: INCY) between the April 15 and April 30 settlement dates. Pharmacyclics (NASDAQ: PCYC) and Regeneron Pharmaceuticals (NASDAQ: REGN) also saw double-digit percentage increases in the number of their...

U.S. stocks fell after the S&P 500 and Nasdaq has risen for six consecutive trading sessions after new home sales data came in worse than expected. Investors could reasonably expect the markets to cool off after six straight days of gains especially as earnings continue to come in mixed....

U.S. stocks rose as investors cheered recent earning reports and a positive home sales data for March. A $45 billion M&A offer also contributed to Tuesday's buying action as investors could be excited and motivated to buy stocks ahead of a few rough weeks of bearish activity. The S&P...

The earnings crunch is underway. Highlights this week include scheduled quarterly reports from Amazon.com, Apple, Facebook, Netflix and Starbucks, which are all expected to post earnings growth, as well as from Ford, McDonald's and Microsoft, for which earnings declines are forecast. Here is a...

U.S. stocks tumbled as investors and traders showed no intention of allowing Wednesday's bull charge to continue. The Nasdaq index continues to under-perform and notched its worst one day performance since 2011. The decline in the Nasdaq index continues to be fueled by biotech and momentum...

In a period when many biotech stocks were slipping, short sellers moved on many of the leading biotech and emerging pharmaceuticals between the March 14 and March 31 settlement dates. But Amgen (NASDAQ: AMGN), Celgene (NASDAQ: CELG) and Dendreon (NASDAQ: DNDN) were among those that bucked the...

The great biotechnology sell-off of 2014 began on February 26 and started as big sell-offs often do: quietly. The SPDR S&P Biotechnology exchange-traded fund (NYSE: XBI) peaked at $172.52 and closed at $170.01, off 40 cents from the day before. The next day, the ETF finished at a record...

After largely shying away in the previous period, short sellers found renewed interest in many of the leading biotech and emerging pharmaceutical companies between the February 28 and March 14 settlement dates. But Celgene (NASDAQ: CELG), Medivation (NASDAQ: MDVN) and Pharmacyclics (NASDAQ: PCYC...

U.S. stocks slipped to negative territory aided in part by Friday being a quadruple witching trading session. Major indices sold off in the afternoon as investors likely took some chips off the table going in to an uncertain weekend with the situation in Ukraine far from resolved. The S&P...

Short interest in most of the leading biotech and emerging pharmaceutical companies declined between the February 14 and February 28 settlement dates. But Biogen Idec (NASDAQ: BIIB), BioMarin Pharmaceutical (NASDAQ: BMRN) and Medivation (NASDAQ: MDVN) bucked that trend. Short interest in Gilead...

Among the leading biotech and emerging pharmaceutical companies, Amgen (NASDAQ: AMGN), Biogen Idec (NASDAQ: BIIB) and BioMarin Pharmaceutical (NASDAQ: BMRN) saw the largest percentage increases in short interest between the January 31 and February 15 settlement dates. Alexion Pharmaceuticals,...

Shares of the following exchange traded funds are trading more than 20 percent higher than 90 days ago, and they are within 10 percent of their 52-week highs. This set of ETFs provides a peek at areas of investor interest during and after the holiday shopping season, as uncertainty over the...